FDA warned 123Herbals that SILINTAN and other herbal products are unapproved drugs, and SILINTAN contains hidden meloxicam.
What happened
FDA reviewed 123Herbals' website from July to November 2025 and found six products sold with claims to treat conditions such as gout, arthritis, bronchitis, kidney problems, diabetes, and gastric pain. FDA also obtained and tested a sample of SILINTAN and found meloxicam, an NSAID, not declared on the label. FDA cited the products as unapproved new drugs and SILINTAN as misbranded because its label omits the hidden drug.
What FDA found
The website claims the six products treat diseases or body functions, so they are intended as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128The six products are new drugs because they are not generally recognized as safe and effective for their claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for the six products, so selling them violates the unapproved-drug provision.
FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)SILINTAN contains meloxicam, an NSAID, but the label does not declare it, so the labeling is false or misleading.
FD&C Act section 502(a), 21 U.S.C. 352(a); section 201(n), 21 U.S.C. 321(n)
What FDA wants
FDA asks 123Herbals to notify it in writing within 15 working days of the specific steps taken to correct the violations, with an explanation and supporting documents. If correction cannot be completed in that time, the company must state the reason and the time needed.
Who should pay attention
- consumers who bought SILINTAN or similar herbal pain products
- online sellers of imported herbal remedies
- quality teams checking product labels and disease-treatment claims
This is a summary. Read the original letter on fda.gov.